Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

Rocha, Talita Máira Bueno da Silveira da; Fortier, Sergio Costa; Fischer, Thais Rodrigues da Cunha; Perini, Guilherme Fleury; Gaiolla, Rafael Dezen; Fogliatto, Laura; Delamain, Marcia Torresan; Costa, Andressa Fragoso da; Castro, Nelson Siqueira de; Barretos, Wolney Gois; Souza, Cármino Antonio de; Buccheri, Valéria; Chiattone, Carlos Sérgio.
Rev. bras. hematol. hemoter ; 39(3): 216-222, July-Sept. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-898924

Documentos relacionados

  1. Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting.
  2. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
  3. Immunotherapy in Hodgkin Lymphoma: The Road Ahead.
  4. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
  5. Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.
  6. Barriers to long-term follow-up in pediatric Hodgkin lymphoma survivors.
  7. Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?
  8. Late-effect awareness and follow-up of cancer in general practice.
  9. A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race.
  10. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.